β2 agonists v placebo for acute bronchitis without underlying pulmonary disease*
| Weighted event rates | |||||
|---|---|---|---|---|---|
| Outcomes | Patient group | β2 agonists | Placebo | RRI (95% CI) | NNH (CI) |
| ST at 3 to 7 days | Children | 11% | 0% | 576% (–14 to 5218) | 9 (5 to 100) |
| Shaking, tremor, or nervousness at 3 to 7 days | Adults† | 55% | 11% | 388% (185 to 758) | 2.3 (2 to 3) |
| RRR (CI) | NNT (CI) | ||||
|---|---|---|---|---|---|
| Cough at > 7 days | Adults | 64% | 71% | 14% (–18 to 37) | Not significant |
| Night cough at > 7 days | Adults | 24% | 29% | 16% (–33 to 46) | Not significant |
| Standardised mean differences (CI) | |||||
|---|---|---|---|---|---|
| *DCSSs = daily cough symptom scores; ST = shaking or tremor. Other abbreviations defined in glossary; RRI, RRR, NNH, NNT, and CI calculated from data in article using random effects. | |||||
| †Event rates provided by author. | |||||
| DCSSs at 3 days | Children | 0.36 (–0.05 to 0.77) | |||
| DCSSs at 4 days | Adults | –0.14 (–0.38 to 0.11) | |||
